Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1

By Julia A. Brown, D. Dorfman, F. Ma, Elizabeth L. Sullivan, O. Muñoz, C. Wood, E. Greenfield, G. Freeman. Journal of Immunology, 2003

987 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/5cad6c001d2fb9fb5f7c8e08755aff520c83f417

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Lieping Chen
2. Arlene H. Sharpe
3. G. Freeman
4. B. Fife
5. D. Pardoll
6. H. Hammad
7. J. Bluestone
8. V. Kuchroo

In Oncology

1. Lieping Chen
2. Arlene H. Sharpe
3. G. Freeman
4. J. Bluestone
5. B. Fife
6. V. Kuchroo
7. M. Hung
8. J. Hsu

Citations in the corpus

• Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways (2008, background): “PD-L1 is expressed on leukocytes, nonhematopoietic cells, and in non-lymphoid tissues including islets (21, 24, 25), while PD-L2 is expressed exclusively on DCs and monocytes (21, 22, 26, 27).”
• B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression (2004, background): “B7-H1 is also abundant on tumor cell lines and tumor tissues, including lung carcinomas, ovarian carcinomas, breast carcinomas, glioblastoma, and squamous cell carcinoma of the head and neck (12, 13, 16, 17).”
• Deubiquitination and Stabilization of PD-L1 by CSN5 (2016, background): “A major feature of immune evasion in cancer cells is the expression of multiple inhibitory ligands, notably the programmed cell death-ligand 1 (PD-L1), on the surface of cancer cells (Dong et al., 2002), dendritic cells (DCs) (Brown et al., 2003), and macrophages (Rodriguez-Garcia et al., 2011).”
• The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. (2006, background): “In the present investigation, we examine the expression patterns of the B7-H1 protein in a larger number of subjects, including 44 breast cancer patients with IDC, to correlate its expression with patients’ clinicopathological data.”
• Essential Role of Lung Plasmacytoid Dendritic Cells in Preventing Asthmatic Reactions to Harmless Inhaled Antigen (2004, background): “Alternatively, pDCs in the lung and MLNs are immature, expressing low levels of MHC II and costimulatory molecules, yet high levels of the inhibitory B7 family member PD-L1 molecule, known to suppress T cell activation through interaction with PD-1 (42).”
• Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018, background): “PD-1 activity is therefore only relevant during simultaneous T cell activation, as its signal transduction can only come into effect during TCRdependent signaling (39, 41, 48).”